Sector News

UK drug contractor to be sold to private equity firm in $1.4B deal

May 30, 2021
Life sciences

The Carlyle Group created Bidco to buy Vectura, which specializes in inhalers and works with major drugmakers from Novartis to GlaxoSmithKline. The company’s technology is used in 13 inhaled and 11 non-inhaled products, according to a statement on the deal.

Vectura also has a portfolio of treatments in development with partners, the companies said, although it’s been less successful in bringing its own drugs to market. Vectura shelved an asthma therapy in 2018 after it failed in a Phase 3 study.

The purchase is part of a wave of investment firms buying up contractors in the pharmaceutical business. With medicines becoming increasingly complex, biotechs and traditional pharma companies are relying more and more on specialists to develop and manufacture new therapies. READ MORE

By Kristin Jensen


comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach